Equities research analysts expect HTG Molecular Diagnostics Inc (NASDAQ:HTGM) to report ($0.20) earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for HTG Molecular Diagnostics’ earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.29). HTG Molecular Diagnostics reported earnings per share of ($0.15) during the same quarter last year, which would indicate a negative year over year growth rate of 33.3%. The company is expected to issue its next earnings report after the market closes on Thursday, March 7th.
On average, analysts expect that HTG Molecular Diagnostics will report full year earnings of ($0.72) per share for the current year, with EPS estimates ranging from ($0.82) to ($0.63). For the next financial year, analysts expect that the business will post earnings of ($0.54) per share, with EPS estimates ranging from ($0.69) to ($0.43). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow HTG Molecular Diagnostics.
Several research analysts have issued reports on HTGM shares. HC Wainwright set a $7.00 target price on HTG Molecular Diagnostics and gave the stock a “buy” rating in a research report on Wednesday, October 24th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $7.00 price objective on shares of HTG Molecular Diagnostics in a research note on Friday, November 9th. Craig Hallum assumed coverage on HTG Molecular Diagnostics in a research note on Monday, November 12th. They issued a “buy” rating and a $8.00 price objective on the stock. Zacks Investment Research downgraded HTG Molecular Diagnostics from a “hold” rating to a “sell” rating in a research note on Thursday, November 15th. Finally, ValuEngine downgraded HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 18th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $6.60.
Institutional investors and hedge funds have recently modified their holdings of the stock. Jane Street Group LLC bought a new stake in HTG Molecular Diagnostics during the 4th quarter valued at approximately $27,000. Raymond James Financial Services Advisors Inc. bought a new stake in HTG Molecular Diagnostics during the 4th quarter valued at approximately $29,000. Virtu Financial LLC bought a new stake in HTG Molecular Diagnostics during the 3rd quarter valued at approximately $215,000. Millennium Management LLC bought a new stake in HTG Molecular Diagnostics during the 4th quarter valued at approximately $151,000. Finally, BlackRock Inc. raised its stake in HTG Molecular Diagnostics by 322.8% during the 2nd quarter. BlackRock Inc. now owns 73,044 shares of the medical research company’s stock valued at $238,000 after purchasing an additional 55,769 shares during the period. 45.45% of the stock is currently owned by institutional investors.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.